On September 12, 2024, ModivCare issued a press release announcing, among other things, that it would "undertak[e] actions to seek additional capital, including filing a shelf registration statement with the U.S. Securities and Exchange Commission to improve its liquidity. On this news, ModivCare's stock price fell $18.43 per share, or 59.09%, to close at $12.76 per share on September 12, 2024. Finally, on September 16, 2024, ModivCare issued a press release in which the Company revised its 2024 Adjusted EBITDA guidance range from $185–$195 million to $170–$180 million, "primarily due to NEMT segment pricing accommodations made to strategically retain and expand key customer relationships." On this news, ModivCare's stock price fell $1.40 per share, or 9.92%, to close at $12.72 per share on September 16, 2024. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation.